ClearPoint Neuro (CLPT)
(Delayed Data from NSDQ)
$6.01 USD
+0.16 (2.74%)
Updated May 14, 2024 04:00 PM ET
After-Market: $5.99 -0.02 (-0.33%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CLPT 6.01 +0.16(2.74%)
Will CLPT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CLPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLPT
Wall Street Analysts Predict a 70.65% Upside in ClearPoint Neuro (CLPT): Here's What You Should Know
Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates
CLPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates
Why ClearPoint Neuro (CLPT) Stock Might be a Great Pick
ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates
Other News for CLPT
Lake Street Keeps Their Buy Rating on ClearPoint Neuro (CLPT)
ClearPoint Neuro: A Strong Buy on Robust Revenue Growth and Strategic Advancements
ClearPoint Neuro Inc (CLPT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth ...
ClearPoint Neuro Reports First Quarter 2024 Results
ClearPoint Neuro, Inc. (CLPT) Q1 2024 Earnings Call Transcript